SK175997A3 - Controlled release formulations for poorly soluble drugs - Google Patents

Controlled release formulations for poorly soluble drugs Download PDF

Info

Publication number: SK175997A3
Authority: SK; Slovakia
Prior art keywords: solid dispersion; formulation according; formulation; tablets; tablet
Prior art date: 1995-07-03

Application number

SK1759-97A

Other languages

English (en)

Slovak (sk)

Inventor

Maurice J A Clancy

Kenneth I Cumming

Michael Myers

Original Assignee

Elan Corp Plc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-07-03

Filing date

1996-07-01

Publication date

1998-06-03

1996-07-01 Application filed by Elan Corp Plc filed Critical Elan Corp Plc

1998-06-03 Publication of SK175997A3 publication Critical patent/SK175997A3/sk

Links

239000000203 mixture Substances 0.000 title claims abstract description 66
238000009472 formulation Methods 0.000 title claims abstract description 44
238000013270 controlled release Methods 0.000 title claims abstract description 7
229940079593 drug Drugs 0.000 title description 16
239000003814 drug Substances 0.000 title description 16
239000003826 tablet Substances 0.000 claims abstract description 80
239000007962 solid dispersion Substances 0.000 claims abstract description 58
229920001983 poloxamer Polymers 0.000 claims abstract description 44
239000004480 active ingredient Substances 0.000 claims abstract description 37
DCSUBABJRXZOMT-IRLDBZIGSA-N cisapride Chemical compound C([C@@H]([C@@H](CC1)NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)OC)N1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-IRLDBZIGSA-N 0.000 claims abstract description 18
229960005132 cisapride Drugs 0.000 claims abstract description 18
229960000502 poloxamer Drugs 0.000 claims abstract description 18
DCSUBABJRXZOMT-UHFFFAOYSA-N cisapride Natural products C1CC(NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)C(OC)CN1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-UHFFFAOYSA-N 0.000 claims abstract description 17
RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims abstract description 16
HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 claims abstract description 16
238000000576 coating method Methods 0.000 claims abstract description 15
229960001597 nifedipine Drugs 0.000 claims abstract description 15
239000011248 coating agent Substances 0.000 claims abstract description 14
239000008185 minitablet Substances 0.000 claims abstract description 13
CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims abstract description 6
ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 claims abstract description 6
230000001225 therapeutic effect Effects 0.000 claims abstract description 6
HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims abstract description 4
229960001680 ibuprofen Drugs 0.000 claims abstract description 4
RZTAMFZIAATZDJ-HNNXBMFYSA-N 5-o-ethyl 3-o-methyl (4s)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-HNNXBMFYSA-N 0.000 claims abstract description 3
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims abstract description 3
229930105110 Cyclosporin A Natural products 0.000 claims abstract description 3
108010036949 Cyclosporine Proteins 0.000 claims abstract description 3
ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 claims abstract description 3
GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims abstract description 3
229960001265 ciclosporin Drugs 0.000 claims abstract description 3
229930182912 cyclosporin Natural products 0.000 claims abstract description 3
DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims abstract description 3
229960001259 diclofenac Drugs 0.000 claims abstract description 3
229960003580 felodipine Drugs 0.000 claims abstract description 3
229960000905 indomethacin Drugs 0.000 claims abstract description 3
229960001783 nicardipine Drugs 0.000 claims abstract description 3
229960000351 terfenadine Drugs 0.000 claims abstract description 3
229960000278 theophylline Drugs 0.000 claims abstract description 3
229920000642 polymer Polymers 0.000 claims description 40
-1 polyethylene Polymers 0.000 claims description 23
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 17
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 17
239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 15
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 15
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
239000012528 membrane Substances 0.000 claims description 11
239000007787 solid Substances 0.000 claims description 10
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 9
239000004094 surface-active agent Substances 0.000 claims description 9
229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 8
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 7
230000002378 acidificating effect Effects 0.000 claims description 7
239000000017 hydrogel Substances 0.000 claims description 7
239000011975 tartaric acid Substances 0.000 claims description 7
235000002906 tartaric acid Nutrition 0.000 claims description 7
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 6
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 6
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 6
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 6
239000002253 acid Substances 0.000 claims description 5
239000004615 ingredient Substances 0.000 claims description 5
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 4
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical group [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 4
239000004698 Polyethylene Substances 0.000 claims description 4
239000002202 Polyethylene glycol Substances 0.000 claims description 4
WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid group Chemical group C(CCCCC(=O)O)(=O)O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 claims description 4
150000002148 esters Chemical class 0.000 claims description 4
239000011159 matrix material Substances 0.000 claims description 4
229920000573 polyethylene Polymers 0.000 claims description 4
229920001223 polyethylene glycol Polymers 0.000 claims description 4
235000019333 sodium laurylsulphate Nutrition 0.000 claims description 4
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 3
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 3
UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 3
235000015165 citric acid Nutrition 0.000 claims description 3
235000019253 formic acid Nutrition 0.000 claims description 3
229910000029 sodium carbonate Inorganic materials 0.000 claims description 3
239000001509 sodium citrate Substances 0.000 claims description 3
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 3
KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 3
BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 2
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical group [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 2
239000001361 adipic acid Substances 0.000 claims description 2
235000011037 adipic acid Nutrition 0.000 claims description 2
150000008051 alkyl sulfates Chemical class 0.000 claims description 2
BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 2
239000011668 ascorbic acid Substances 0.000 claims description 2
235000010323 ascorbic acid Nutrition 0.000 claims description 2
229960005070 ascorbic acid Drugs 0.000 claims description 2
229910000019 calcium carbonate Inorganic materials 0.000 claims description 2
AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 claims description 2
239000000920 calcium hydroxide Substances 0.000 claims description 2
229910001861 calcium hydroxide Inorganic materials 0.000 claims description 2
150000007942 carboxylates Chemical class 0.000 claims description 2
VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 claims description 2
239000000347 magnesium hydroxide Substances 0.000 claims description 2
229910001862 magnesium hydroxide Inorganic materials 0.000 claims description 2
239000001630 malic acid Substances 0.000 claims description 2
235000011090 malic acid Nutrition 0.000 claims description 2
229910052708 sodium Inorganic materials 0.000 claims description 2
239000011734 sodium Substances 0.000 claims description 2
239000001384 succinic acid Substances 0.000 claims 1
235000011044 succinic acid Nutrition 0.000 claims 1
239000008188 pellet Substances 0.000 abstract description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 24
238000002360 preparation method Methods 0.000 description 22
VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 17
239000007916 tablet composition Substances 0.000 description 17
229920003134 Eudragit® polymer Polymers 0.000 description 16
238000004090 dissolution Methods 0.000 description 16
239000006185 dispersion Substances 0.000 description 15
238000000338 in vitro Methods 0.000 description 14
235000019359 magnesium stearate Nutrition 0.000 description 12
238000002156 mixing Methods 0.000 description 11
229920003095 Methocel™ K15M Polymers 0.000 description 10
239000000546 pharmaceutical excipient Substances 0.000 description 10
230000036470 plasma concentration Effects 0.000 description 10
238000010521 absorption reaction Methods 0.000 description 9
239000000243 solution Substances 0.000 description 9
229920003093 Methocel™ K100 LV Polymers 0.000 description 8
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
239000000945 filler Substances 0.000 description 8
229920003169 water-soluble polymer Polymers 0.000 description 8
229910002016 Aerosil® 200 Inorganic materials 0.000 description 7
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 7
239000002775 capsule Substances 0.000 description 7
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
229920002678 cellulose Polymers 0.000 description 6
239000001913 cellulose Substances 0.000 description 6
235000010980 cellulose Nutrition 0.000 description 6
239000002552 dosage form Substances 0.000 description 6
GUBGYTABKSRVRQ-QKKXKWKRSA-N lactose group Chemical group OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 6
239000000463 material Substances 0.000 description 6
230000035699 permeability Effects 0.000 description 6
239000002904 solvent Substances 0.000 description 6
238000003756 stirring Methods 0.000 description 6
229920003091 Methocel™ Polymers 0.000 description 5
239000003795 chemical substances by application Substances 0.000 description 5
239000008101 lactose Substances 0.000 description 5
229960001375 lactose Drugs 0.000 description 5
230000001419 dependent effect Effects 0.000 description 4
238000010586 diagram Methods 0.000 description 4
238000009792 diffusion process Methods 0.000 description 4
230000000694 effects Effects 0.000 description 4
210000001035 gastrointestinal tract Anatomy 0.000 description 4
238000000034 method Methods 0.000 description 4
DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Substances CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 4
239000000725 suspension Substances 0.000 description 4
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
239000002156 adsorbate Substances 0.000 description 3
239000007864 aqueous solution Substances 0.000 description 3
239000012752 auxiliary agent Substances 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
238000007906 compression Methods 0.000 description 3
230000006835 compression Effects 0.000 description 3
229920001577 copolymer Polymers 0.000 description 3
239000005038 ethylene vinyl acetate Substances 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 3
229920005862 polyol Polymers 0.000 description 3
229920001451 polypropylene glycol Polymers 0.000 description 3
239000000126 substance Substances 0.000 description 3
229920002554 vinyl polymer Polymers 0.000 description 3
NIQCNGHVCWTJSM-UHFFFAOYSA-N Dimethyl phthalate Chemical compound COC(=O)C1=CC=CC=C1C(=O)OC NIQCNGHVCWTJSM-UHFFFAOYSA-N 0.000 description 2
CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 2
CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 2
229920000168 Microcrystalline cellulose Polymers 0.000 description 2
NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
230000000052 comparative effect Effects 0.000 description 2
DOIRQSBPFJWKBE-UHFFFAOYSA-N dibutyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 description 2
125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 2
238000012377 drug delivery Methods 0.000 description 2
239000007903 gelatin capsule Substances 0.000 description 2
150000001261 hydroxy acids Chemical class 0.000 description 2
239000012535 impurity Substances 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
229940016286 microcrystalline cellulose Drugs 0.000 description 2
235000019813 microcrystalline cellulose Nutrition 0.000 description 2
239000008108 microcrystalline cellulose Substances 0.000 description 2
150000002772 monosaccharides Chemical class 0.000 description 2
239000003960 organic solvent Substances 0.000 description 2
239000002245 particle Substances 0.000 description 2
239000004014 plasticizer Substances 0.000 description 2
229920001483 poly(ethyl methacrylate) polymer Polymers 0.000 description 2
229920003229 poly(methyl methacrylate) Polymers 0.000 description 2
239000004926 polymethyl methacrylate Substances 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
229960004063 propylene glycol Drugs 0.000 description 2
239000008213 purified water Substances 0.000 description 2
238000013268 sustained release Methods 0.000 description 2
239000012730 sustained-release form Substances 0.000 description 2
239000000454 talc Substances 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
229920003176 water-insoluble polymer Polymers 0.000 description 2
YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical class C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 description 1
SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
239000004925 Acrylic resin Substances 0.000 description 1
229920000178 Acrylic resin Polymers 0.000 description 1
229910002012 Aerosil® Inorganic materials 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
241001609030 Brosme brosme Species 0.000 description 1
229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
229920008347 Cellulose acetate propionate Polymers 0.000 description 1
DQEFEBPAPFSJLV-UHFFFAOYSA-N Cellulose propionate Chemical compound CCC(=O)OCC1OC(OC(=O)CC)C(OC(=O)CC)C(OC(=O)CC)C1OC1C(OC(=O)CC)C(OC(=O)CC)C(OC(=O)CC)C(COC(=O)CC)O1 DQEFEBPAPFSJLV-UHFFFAOYSA-N 0.000 description 1
229920002284 Cellulose triacetate Polymers 0.000 description 1
229920001661 Chitosan Polymers 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
229920000858 Cyclodextrin Polymers 0.000 description 1
PYGXAGIECVVIOZ-UHFFFAOYSA-N Dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 description 1
229920005682 EO-PO block copolymer Polymers 0.000 description 1
239000001856 Ethyl cellulose Substances 0.000 description 1
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
229920003136 Eudragit® L polymer Polymers 0.000 description 1
229920003137 Eudragit® S polymer Polymers 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
241000721662 Juniperus Species 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
229920003096 Methocel™ K100M Polymers 0.000 description 1
229920003094 Methocel™ K4M Polymers 0.000 description 1
244000046052 Phaseolus vulgaris Species 0.000 description 1
235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
229920002319 Poly(methyl acrylate) Polymers 0.000 description 1
239000004372 Polyvinyl alcohol Substances 0.000 description 1
GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
229920001800 Shellac Polymers 0.000 description 1
239000004280 Sodium formate Substances 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
NNLVGZFZQQXQNW-ADJNRHBOSA-N [(2r,3r,4s,5r,6s)-4,5-diacetyloxy-3-[(2s,3r,4s,5r,6r)-3,4,5-triacetyloxy-6-(acetyloxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6s)-4,5,6-triacetyloxy-2-(acetyloxymethyl)oxan-3-yl]oxyoxan-2-yl]methyl acetate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](OC(C)=O)[C@H]1OC(C)=O)O[C@H]1[C@@H]([C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(C)=O)O1)OC(C)=O)COC(=O)C)[C@@H]1[C@@H](COC(C)=O)O[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O NNLVGZFZQQXQNW-ADJNRHBOSA-N 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
150000001252 acrylic acid derivatives Chemical class 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
239000008272 agar Substances 0.000 description 1
235000010419 agar Nutrition 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
150000003863 ammonium salts Chemical class 0.000 description 1
125000000129 anionic group Chemical group 0.000 description 1
229920006318 anionic polymer Polymers 0.000 description 1
229920001400 block copolymer Polymers 0.000 description 1
239000000872 buffer Substances 0.000 description 1
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
239000000679 carrageenan Substances 0.000 description 1
235000010418 carrageenan Nutrition 0.000 description 1
229920001525 carrageenan Polymers 0.000 description 1
229940113118 carrageenan Drugs 0.000 description 1
239000000969 carrier Substances 0.000 description 1
125000002091 cationic group Chemical group 0.000 description 1
229920002301 cellulose acetate Polymers 0.000 description 1
229920006217 cellulose acetate butyrate Polymers 0.000 description 1
229940081734 cellulose acetate phthalate Drugs 0.000 description 1
229920006218 cellulose propionate Polymers 0.000 description 1
229920003174 cellulose-based polymer Polymers 0.000 description 1
229920001688 coating polymer Polymers 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
229920006037 cross link polymer Polymers 0.000 description 1
229940097362 cyclodextrins Drugs 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
229940099371 diacetylated monoglycerides Drugs 0.000 description 1
125000004925 dihydropyridyl group Chemical group N1(CC=CC=C1)* 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
FBSAITBEAPNWJG-UHFFFAOYSA-N dimethyl phthalate Natural products CC(=O)OC1=CC=CC=C1OC(C)=O FBSAITBEAPNWJG-UHFFFAOYSA-N 0.000 description 1
229960001826 dimethylphthalate Drugs 0.000 description 1
238000007907 direct compression Methods 0.000 description 1
150000002016 disaccharides Chemical class 0.000 description 1
239000012738 dissolution medium Substances 0.000 description 1
238000009509 drug development Methods 0.000 description 1
239000002662 enteric coated tablet Substances 0.000 description 1
229920001249 ethyl cellulose Polymers 0.000 description 1
235000019325 ethyl cellulose Nutrition 0.000 description 1
238000011049 filling Methods 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
229960005150 glycerol Drugs 0.000 description 1
239000001087 glyceryl triacetate Substances 0.000 description 1
235000013773 glyceryl triacetate Nutrition 0.000 description 1
229920001903 high density polyethylene Polymers 0.000 description 1
239000004700 high-density polyethylene Substances 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
239000012729 immediate-release (IR) formulation Substances 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
229960001021 lactose monohydrate Drugs 0.000 description 1
239000007788 liquid Substances 0.000 description 1
229920001684 low density polyethylene Polymers 0.000 description 1
239000004702 low-density polyethylene Substances 0.000 description 1
210000003750 lower gastrointestinal tract Anatomy 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
150000002734 metacrylic acid derivatives Chemical class 0.000 description 1
125000005397 methacrylic acid ester group Chemical group 0.000 description 1
125000005395 methacrylic acid group Chemical class 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
238000009462 micro packaging Methods 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
239000006186 oral dosage form Substances 0.000 description 1
125000006353 oxyethylene group Chemical group 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
229920000212 poly(isobutyl acrylate) Polymers 0.000 description 1
229920000184 poly(octadecyl acrylate) Polymers 0.000 description 1
229920000197 polyisopropyl acrylate Polymers 0.000 description 1
229920002959 polymer blend Polymers 0.000 description 1
229920006254 polymer film Polymers 0.000 description 1
229920000193 polymethacrylate Polymers 0.000 description 1
229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
229920001296 polysiloxane Polymers 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
239000012254 powdered material Substances 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
125000001453 quaternary ammonium group Chemical group 0.000 description 1
239000002994 raw material Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
239000011347 resin Substances 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
239000004208 shellac Substances 0.000 description 1
ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
229940113147 shellac Drugs 0.000 description 1
235000013874 shellac Nutrition 0.000 description 1
235000017550 sodium carbonate Nutrition 0.000 description 1
HLBBKKJFGFRGMU-UHFFFAOYSA-M sodium formate Chemical compound [Na+].[O-]C=O HLBBKKJFGFRGMU-UHFFFAOYSA-M 0.000 description 1
235000019254 sodium formate Nutrition 0.000 description 1
239000011877 solvent mixture Substances 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
229910001220 stainless steel Inorganic materials 0.000 description 1
239000010935 stainless steel Substances 0.000 description 1
238000003860 storage Methods 0.000 description 1
230000008961 swelling Effects 0.000 description 1
238000009492 tablet coating Methods 0.000 description 1
239000002700 tablet coating Substances 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
229960002622 triacetin Drugs 0.000 description 1
WEAPVABOECTMGR-UHFFFAOYSA-N triethyl 2-acetyloxypropane-1,2,3-tricarboxylate Chemical compound CCOC(=O)CC(C(=O)OCC)(OC(C)=O)CC(=O)OCC WEAPVABOECTMGR-UHFFFAOYSA-N 0.000 description 1
239000001069 triethyl citrate Substances 0.000 description 1
VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
235000013769 triethyl citrate Nutrition 0.000 description 1
210000002438 upper gastrointestinal tract Anatomy 0.000 description 1
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
229920001285 xanthan gum Polymers 0.000 description 1
UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release

Landscapes

Health & Medical Sciences (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

SK1759-97A 1995-07-03 1996-07-01 Controlled release formulations for poorly soluble drugs SK175997A3 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
IE950492A IE80467B1 (en)	1995-07-03	1995-07-03	Controlled release formulations for poorly soluble drugs
US89795P	1995-07-06	1995-07-06
PCT/IE1996/000039 WO1997002017A1 (en)	1995-07-03	1996-07-01	Controlled release formulations for poorly soluble drugs

Publications (1)

Publication Number	Publication Date
SK175997A3 true SK175997A3 (en)	1998-06-03

Family

ID=26319833

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK1759-97A SK175997A3 (en)	1995-07-03	1996-07-01	Controlled release formulations for poorly soluble drugs

Country Status (20)

Country	Link
EP (1)	EP0836475B1 (cs)
JP (1)	JPH11508587A (cs)
KR (1)	KR19990028693A (cs)
AT (1)	ATE208192T1 (cs)
AU (1)	AU700654B2 (cs)
BG (1)	BG102228A (cs)
BR (1)	BR9609663A (cs)
CA (1)	CA2226008A1 (cs)
CZ (1)	CZ413497A3 (cs)
DE (1)	DE69616795T2 (cs)
HU (1)	HUP9900231A2 (cs)
IE (1)	IE80467B1 (cs)
IL (1)	IL122663A0 (cs)
NO (1)	NO975872L (cs)
NZ (1)	NZ311145A (cs)
PL (1)	PL324402A1 (cs)
SK (1)	SK175997A3 (cs)
TW (1)	TW426528B (cs)
WO (1)	WO1997002017A1 (cs)
ZA (1)	ZA965609B (cs)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IT1283029B1 (it) *	1996-05-17	1998-04-03	Resa Farma	Composizioni farmaceutiche a base di diclofenac
BE1009856A5 (fr)	1995-07-14	1997-10-07	Sandoz Sa	Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
JP2000502066A (ja) *	1995-12-01	2000-02-22	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	徐放性シサプリド
EP0951278A2 (en) *	1997-01-03	1999-10-27	ELAN CORPORATION, Plc	Sustained release cisapride mini-tablet formulation
DE19710009A1 (de) *	1997-03-12	1998-09-24	Knoll Ag	Mehrphasige wirkstoffhaltige Zubereitungsformen
US6312724B1 (en)	1997-04-04	2001-11-06	Isa Odidi	Sustained release pharmaceutical matrix tablet of pharmaceutically acceptable salts of diclofenac and process for preparation thereof
NZ328751A (en) *	1997-09-16	1999-01-28	Bernard Charles Sherman	Solid medicament containing an anionic surfactant and cyclosporin
US6013280A (en) *	1997-10-07	2000-01-11	Fuisz Technologies Ltd.	Immediate release dosage forms containing microspheres
KR20000069356A (ko) *	1997-10-07	2000-11-25	리차드 디. 슈미트	급속방출식 약물전달 제형
NZ333474A (en) *	1998-01-02	1999-06-29	Mcneil Ppc Inc	A chewable tablet containing ibuprofen, fumaric acid and a non hydrocolloid binder e.g. a wax or a fat
IE980115A1 (en) *	1998-02-16	2000-02-09	Biovail Internat Ltd	Solubilizing delivery systems and method of manufacture
US6787157B1 (en)	1998-03-10	2004-09-07	Abbott Laboratories	Multiphase active ingredient-containing formulations
JP2002517431A (ja) *	1998-06-11	2002-06-18	イーエムインダストリーズインコーポレイテッド	マイクロ浸透圧制御薬物送達システム
TW407058B (en) *	1998-07-17	2000-10-01	Dev Center Biotechnology	Oral cisapride dosage forms with an extended duration
IE981008A1 (en) *	1998-12-02	2000-06-14	Fuisz Internat Ltd	Microparticles Containing Water Insoluble Active Agents
ES2310164T3 (es) *	1999-02-10	2009-01-01	Pfizer Products Inc.	Dispositivo de liberacion controlada por la matriz.
US6706283B1 (en)	1999-02-10	2004-03-16	Pfizer Inc	Controlled release by extrusion of solid amorphous dispersions of drugs
EP1064938A1 (en) *	1999-06-28	2001-01-03	Sanofi-Synthelabo	Pharmaceutical dosage forms for controlled release producing at least a timed pulse
SE9902742D0 (sv) *	1999-07-20	1999-07-20	Astra Ab	New pharmaceutical formultion
KR100379299B1 (ko) *	2000-01-15	2003-04-10	주식회사 중외제약	펠로디핀의 가용화 방법 및 방출제어형 제제
US7067148B2 (en)	2001-02-15	2006-06-27	King Pharmaceutical Research & Development, Inc.	Stabilized pharmaceutical and thyroid hormone compositions and method of preparation
HU229938B1 (en) *	2001-05-03	2015-01-28	Hoffmann La Roche	Pharmaceutical dosage form of amorphous nelfinavir mesylate
AR033711A1 (es) *	2001-05-09	2004-01-07	Novartis Ag	Composiciones farmaceuticas
US7101569B2 (en)	2001-08-14	2006-09-05	Franz G Andrew	Methods of administering levothyroxine pharmaceutical compositions
TWI252111B (en) *	2001-12-14	2006-04-01	Solvay Pharm Gmbh	Matrix film tablet with controlled release of a natural mixture of conjugated estrogens
US20050232995A1 (en)	2002-07-29	2005-10-20	Yam Nyomi V	Methods and dosage forms for controlled delivery of paliperidone and risperidone
KR20040011248A (ko) *	2002-07-30	2004-02-05	환인제약 주식회사	암로디핀의 고체분산체와 그 제조방법 및 그를 포함하는약학적 조성물
AU2002350719A1 (en) *	2002-11-29	2004-06-23	Janssen Pharmaceutica N.V.	Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
WO2004066981A1 (en) *	2003-01-29	2004-08-12	Sun Pharmaceutical Industries Limited	Oral controlled release pharmaceutical composition containing metaxalone as active agent
JP2006518380A (ja)	2003-01-31	2006-08-10	スミスクライン・ビーチャム・コーポレイション	固体分散体組成物
CA2520660C (en) *	2003-03-28	2013-08-20	Sigmoid Biotechnologies Limited	Solid oral dosage form containing seamless microcapsules
EP1682092A2 (en) *	2003-11-13	2006-07-26	Alza Corporation	Melt blend dispersions comprising a low water solubility drug and an ethylene oxide-propylene oxide block copolymer
WO2005065653A1 (en) *	2003-12-19	2005-07-21	E.I. Du Pont De Nemours And Company	Intimate coating of ibuprofen with poloxamers to enhance aqueous dissolution
BRPI0418330A (pt)	2003-12-31	2007-05-02	Pfizer Prod Inc	composições sólidas de drogas de solubilidade baixa e poloxámeros
KR100598326B1 (ko)	2004-04-10	2006-07-10	한미약품 주식회사	ＨＭＧ-ＣｏＡ 환원효소 억제제의 경구투여용 서방형 제제및 이의 제조방법
EP1968542B1 (en) *	2005-12-16	2013-08-14	Hanmi Science Co., Ltd.	Solid dispersion comprising an active ingredient having a low melting point and tablet for oral administration comprising same
RU2454220C2 (ru)	2006-08-16	2012-06-27	Новартис Аг	Способ получения твердых дисперсий высококристаллических терапевтических соединений
WO2008120131A2 (en) *	2007-03-30	2008-10-09	Wockhardt Research Centre	Pharmaceutical compositions of diclofenac and misoprostol
EP2079456B1 (en)	2007-04-04	2012-12-05	Sigmoid Pharma Limited	Pharmaceutical cyclosporin compositions
EP2586428B1 (en)	2007-04-26	2023-11-08	Sublimity Therapeutics Limited	Manufacture of multiple minicapsules
JP6222924B2 (ja)	2009-04-24	2017-11-01	イシューティカピーティーワイリミテッド	ジクロフェナクの新規製剤
ES2649112T3 (es)	2009-05-18	2018-01-10	Sigmoid Pharma Limited	Composición que comprende gotas de aceite
CN107582526A (zh)	2009-08-12	2018-01-16	希格默伊德药业有限公司	包含聚合物基质和油相的免疫调节组合物
FR2967576B1 (fr) *	2010-11-18	2013-07-12	Advicenne Pharma	Composition pharmaceutique comprenant du sel precurseur du cycle de krebs, en particulier du sel de citrate, et son utilisation comme medicament
FR2967577B1 (fr) *	2010-11-18	2013-07-12	Advicenne Pharma	Composition pharmaceutique comprenant du sel de bicarbonate, et son utilisation comme medicament
GB201020032D0 (en)	2010-11-25	2011-01-12	Sigmoid Pharma Ltd	Composition
DE102012105512A1 (de) *	2012-06-25	2014-04-24	Hennig Arzneimittel Gmbh & Co. Kg	Arzneiform zur verlängerten Freisetzung von Wirkstoffen
GB201212010D0 (en)	2012-07-05	2012-08-22	Sigmoid Pharma Ltd	Formulations
CN102784128B (zh) *	2012-07-31	2015-01-07	北京协和药厂	一种非洛地平缓释制剂及其制备方法
GB201319791D0 (en)	2013-11-08	2013-12-25	Sigmoid Pharma Ltd	Formulations
US9526734B2 (en)	2014-06-09	2016-12-27	Iceutica Pty Ltd.	Formulation of meloxicam
EP3881829A1 (en)	2014-11-07	2021-09-22	Sublimity Therapeutics Limited	Compositions comprising cyclosporin
EP3793527A1 (en) *	2018-05-14	2021-03-24	Capsugel Belgium NV	Solid dosage forms with high active agent loading
CN113350309B (zh) *	2021-08-09	2021-11-12	北京五和博澳药业股份有限公司	一种难溶性药物渗透泵控释片剂及其制备方法
WO2025253272A1 (en) *	2024-06-05	2025-12-11	Chiaphua Industries Ltd.	Quick,self-dissolving,foamable antimicrobial tablet and method of preparation thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE76292T1 (de) *	1987-11-25	1992-06-15	American Cyanamid Co	System fuer die verzoegerte (kontrollierte) freisetzung von substituierten dihydropyridincalciumantagonisten.

1995
- 1995-07-03 IE IE950492A patent/IE80467B1/en not_active IP Right Cessation
1996
- 1996-07-01 KR KR1019970710016A patent/KR19990028693A/ko not_active Ceased
- 1996-07-01 WO PCT/IE1996/000039 patent/WO1997002017A1/en not_active Ceased
- 1996-07-01 BR BR9609663A patent/BR9609663A/pt not_active Application Discontinuation
- 1996-07-01 SK SK1759-97A patent/SK175997A3/sk unknown
- 1996-07-01 AT AT96921053T patent/ATE208192T1/de active
- 1996-07-01 NZ NZ311145A patent/NZ311145A/xx unknown
- 1996-07-01 AU AU62394/96A patent/AU700654B2/en not_active Ceased
- 1996-07-01 JP JP9504959A patent/JPH11508587A/ja active Pending
- 1996-07-01 PL PL96324402A patent/PL324402A1/xx unknown
- 1996-07-01 EP EP96921053A patent/EP0836475B1/en not_active Expired - Lifetime
- 1996-07-01 HU HU9900231A patent/HUP9900231A2/hu unknown
- 1996-07-01 CZ CZ974134A patent/CZ413497A3/cs unknown
- 1996-07-01 IL IL12266396A patent/IL122663A0/xx unknown
- 1996-07-01 CA CA002226008A patent/CA2226008A1/en not_active Abandoned
- 1996-07-01 DE DE69616795T patent/DE69616795T2/de not_active Expired - Fee Related
- 1996-07-02 ZA ZA965609A patent/ZA965609B/xx unknown
- 1996-08-28 TW TW085110466A patent/TW426528B/zh not_active IP Right Cessation
1997
- 1997-12-12 NO NO975872A patent/NO975872L/no not_active Application Discontinuation
1998
- 1998-02-02 BG BG102228A patent/BG102228A/xx unknown

Also Published As

Publication number	Publication date
DE69616795T2 (de)	2002-08-08
EP0836475B1 (en)	2001-11-07
KR19990028693A (ko)	1999-04-15
ATE208192T1 (de)	2001-11-15
BG102228A (en)	1998-10-30
NO975872L (no)	1998-03-03
BR9609663A (pt)	1999-05-18
HUP9900231A2 (hu)	1999-06-28
PL324402A1 (en)	1998-05-25
IL122663A0 (en)	1998-08-16
EP0836475A1 (en)	1998-04-22
ZA965609B (en)	1997-01-27
NZ311145A (en)	1999-06-29
JPH11508587A (ja)	1999-07-27
IE80467B1 (en)	1998-07-29
CZ413497A3 (cs)	1998-04-15
DE69616795D1 (de)	2001-12-13
TW426528B (en)	2001-03-21
CA2226008A1 (en)	1997-01-23
AU6239496A (en)	1997-02-05
NO975872D0 (no)	1997-12-12
WO1997002017A1 (en)	1997-01-23
AU700654B2 (en)	1999-01-14
MX9710413A (es)	1998-07-31

Publication	Publication Date	Title
SK175997A3 (en)	1998-06-03	Controlled release formulations for poorly soluble drugs
AU2004268663B2 (en)	2010-12-09	Sustained release dosage forms of ziprasidone
EP2079446B1 (en)	2011-10-26	Paliperidone sustained release formulation
US20040052844A1 (en)	2004-03-18	Time-controlled, sustained release, pharmaceutical composition containing water-soluble resins
SK153497A3 (en)	1998-04-08	Three-phase pharmaceutical form with constant and controlled release of amorphous active ingredient for single daily application
EP2373319B1 (en)	2013-07-31	Sustained release pharmaceutical composition of quetiapine and process for preparation thereof
AU731693B2 (en)	2001-04-05	Drug formulation having controlled release of active compound
EP2326312A1 (en)	2011-06-01	Paliperidone composition comprising solid matrix particles
US20260007661A1 (en)	2026-01-08	Extended release upadacitinib formulations
CZ20024216A3 (cs)	2003-04-16	Přípravky s chinolonovými antibiotiky s prodlouženým účinkem a způsob jejich výroby
JP2020070260A (ja)	2020-05-07	テネリグリプチン含有医薬組成物、テネリグリプチン含有医薬組成物の製造方法、テネリグリプチン含有錠剤及びテネリグリプチン含有錠剤の製造方法
JP3110794B2 (ja)	2000-11-20	１，４−ジヒドロピリジン誘導体を含有する製剤
US20100285125A1 (en)	2010-11-11	Delivery system for poorly soluble drugs
US20100055177A1 (en)	2010-03-04	Modified release composition of levetiracetam and process for the preparation thereof
EP2190419A1 (en)	2010-06-02	Multi particulate matrix system containing galantamine
EP2231124A1 (en)	2010-09-29	Sustained-release pharmaceutical formulation containing an antimuscarinic agent and a wetting agent as well as a process for the preparation thereof
KR101175816B1 (ko)	2012-08-24	경구 서방성 정제
JP3007387B2 (ja)	2000-02-07	徐放性製剤用基剤粉末
KR20110130382A (ko)	2011-12-05	생체접착성 컴팩트 매트릭스의 제조방법
WO2003030920A9 (en)	2003-06-26	An antispasmodic agent spaced drug delivery system
US20070160667A1 (en)	2007-07-12	Controlled release formulation of divalproex sodium
WO2023044024A1 (en)	2023-03-23	Novel ph dependent coating drug delivery system
MXPA97010413A (en)	1998-11-09	Controlled release formulations for poorly solub medications
AU2006335344A1 (en)	2007-07-19	Controlled release formulation of divalproic acid and its derivatives
WO2012127048A1 (en)	2012-09-27	Solid pharmaceutical composition comprising donepezil